Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2014, Article ID 429291, 11 pages
Research Article

Long-Term Risperidone Treatment Induces Visceral Adiposity Associated with Hepatic Steatosis in Mice: A Magnetic Resonance Approach

1Université Lille Nord de France, 59000 Lille, France
2Département de Pharmacologie Médicale, CHULille, EA 1046, 59000 Lille, France
3Inserm, U837, 59000 Lille, France
4IMPRT-IFR114, 59000 Lille, France
5Faculté de Pharmacie, 59006 Lille, France
6Inserm, U1011, 59000 Lille, France
7Institut Pasteur de Lille, 59019 Lille, France
8UArtois, 62300 Lens, France
9Laboratoire de Pharmacologie Médicale, EA 1046, Faculté de Médecine, Université Lille2, Pôle Recherche, 1 Place de Verdun, 59045 Lille Cedex, France

Received 28 July 2013; Accepted 3 April 2014; Published 27 April 2014

Academic Editor: Sonia Dollfus

Copyright © 2014 Florent Auger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Although atypical antipsychotic drugs (APDs) have led to significant advances in the treatment of psychotic disorders, they still induce metabolic disturbances. We aimed at characterizing the metabolic consequences of a risperidone treatment and at establishing a link with noninvasive MR markers, in order to develop a tool for predicting symptoms of the metabolic syndrome. Fat deposition and liver morphometry were assessed by T1-weighted imaging. Fatty acid composition and fat accumulations in tissues were determined using MR spectroscopy with and without water suppression, respectively. Risperidone treatment induced a weight gain accompanied with metabolic disturbances such as hyperglycemic status, an increase in visceral adipose tissue (VAT), and liver fat depositions. Correlations using Methylene-Water Ratio (MWR) and Polyunsaturated Index (PUI) demonstrated a concomitant increase in the weight gain, VAT and liver fat depositions, and a decrease in the quantity of polyunsaturated fatty acids. These results were consistent with a hepatic steatosis state. We evaluated the ability of MR techniques to detect subtle metabolic disorders induced by APDs. Thus, our model and methodology offer the possibility to investigate APDs side effects in order to improve the health conditions of schizophrenic patients.